James Robinson's investment in Alkermes, where he has been CEO since March 2018, reflects his commitment to the company. He has a significant stake in the company, including vested stock options and awards that have appreciated over time. When he...

James Robinson's investment in Alkermes, where he has been CEO since March 2018, reflects his commitment to the company. He has a significant stake in the company, including vested stock options and awards that have appreciated over time. When he joined, his total vested stock was valued around $6 million in 2023, a noticeable increase since his start. Robinson's holdings have varied over the years, but he consistently has high-value stock options. This growth in value indicates strong performance expectations with the company's plans and ambitions in the healthcare market, particularly focusing on treatments for severe mental illnesses and addiction.